A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Official title

A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer

Overview

To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer

Interventions

• Drug TQB6411 for Injection
  TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle.

Primary outcome measures

• Recommended Phase II Dosage for the Treatment (RP2D) [Time frame: Baseline up to 21 days]
• Objective Response Rate (ORR) [Time frame: Baseline up to 6 mouths]

Secondary outcome measures (8)

• Disease Control Rate (DCR) [Time frame: Baseline up to 6 mouths]
• Duration of Relief (DOR) [Time frame: Baseline up to 2 years]
• Progression-Free Survival [Time frame: Baseline up to 2 years]
• Overall Survival (OS) [Time frame: Baseline up to 3 years]
• Adverse Events (AE) [Time frame: Baseline up to 2 years]
• Incidence of Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) [Time frame: Cycle 1 day 1, Cycle 4 day 1, Cycle 6 day 1, Cycle 12 daye 1: 60 minutes before administration (21 days as a treatment cycle)]
• Peak concentration (Cmax) [Time frame: Before administration, 30 minuets, 15 minuets after administration]
• Plasma concentration at steady state (Cav, SS) [Time frame: Pre-dose of day 1 on multiple dose and 2, 6, 24, 72 hours, 7, 14 days post-dose on multiple dose of day 1]

Eligibility criteria

Inclusion criteria

• Subjects voluntarily participate in this study, sign the informed consent form, and demonstrate good compliance;
• Age between 18 and 75 years (calculated based on the date of signing the informed consent form);
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
• Expected survival greater than 12 weeks;
• At least one measurable lesion according to RECIST v1.1 criteria;
• Laboratory test results meeting the following criteria (no blood transfusion within 14 days or hematopoietic growth factor administration within 7 days prior to screening):

• Hemoglobin (HGB) ≥ 90 g/L;
• Absolute neutrophil count (NEUT) ≥ 1.5×10⁹/L;
• Platelet count (PLT) ≥ 90×10⁹/L;
• Total bilirubin (TBIL) ≤ 1.5×Upper Limit of Normal (ULN);
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5×ULN (≤ 5×ULN if liver metastases are present);
• Serum creatinine (CR) ≤ 1.3×ULN or creatinine clearance rate (CCR) ≥ 50 mL/min;
• Prothrombin time (PT), activated partial thromboplastin time (APTT), and international normalized ratio (INR) ≤ 1.5×ULN (no anticoagulant therapy within the past 2 weeks);
• Lung cancer confirmed by histology or cytology；
• Willing to provide qualified tumor tissue samples for immunohistochemical testing and amplification, unless the subject has no eligible archived specimens and is unsuitable or refuses re-biopsy;
• Women of childbearing potential must agree to use effective contraception during the study and for 6 months after study completion, with a negative serum or urine pregnancy test within 7 days before enrollment; male subjects must agree to use effective contraception during the study and for 6 months after study completion (see Section 5.5 for details).

Exclusion criteria

• History of or concurrent other malignancies, except for: other malignancies treated with surgery alone and achieving ≥5 years of disease-free survival (DFS); or cured carcinoma in situ of cervix, non-melanoma skin cancer, or superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading basement membrane)\].
• Diseases affecting intravenous injection or blood sampling.
• Adverse reactions from prior therapies not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 grade ≤1, except for: grade 2 alopecia, grade 2 peripheral neuropathy, grade 2 anemia, non-clinically significant asymptomatic grade 2 laboratory abnormalities, hypothyroidism stabilized with hormone replacement, or other toxicities judged by investigator as non-safety risks.
• Major surgery (Grade 3 or above per National Surgical Classification Catalog 2022), significant traumatic injury within 4 weeks prior to first dose, planned major surgery during study (except protocol-specified procedures), or presence of unhealed wounds/fractures.
• Any bleeding or hemorrhagic events ≥CTCAE grade 3 within 4 weeks prior to first dose.
• Arterial/venous thromboembolic events within 6 months prior to first dose, including: cerebrovascular accidents (including transient ischemic attack (TIA), excluding lacunar infarction), deep vein thrombosis, or pulmonary embolism (implantable venous port- or catheter-related thrombosis or superficial venous thrombosis not considered "severe" thromboembolism).
• Active viral hepatitis with poor control, except: hepatitis B surface antigen (HBsAg)-positive subjects with Hepatitis B virus Deoxyribonucleic acid (HBV DNA) <500 IU/mL (2500 copies/mL) who agree to receive anti-HBV therapy throughout study; or hepatitis C virus (HCV)-infected subjects (Hepatitis C Virus Antibody or Ribonucleic Acid positive) with hepatitis C virus Ribonucleic Acid (HCV RNA) ≤ULN continuing approved antiviral therapy.
• Active syphilis requiring treatment.
• Active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced/radiation pneumonitis requiring treatment, clinically significant active pneumonia, history of interstitial lung disease (ILD) requiring treatment, or current ILD.
• History of psychotropic drug abuse or mental disorders.
• Prior or planned allogeneic bone marrow or solid organ transplantation.
• History of hepatic encephalopathy.
• Significant cardiovascular diseases including:

• Cardiac dysfunction ≥New York Heart Association (NYHA) class II or Left Ventricular Ejection Fractions (LVEF) <50% by echocardiography;
• Clinically significant ventricular arrhythmia history (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or arrhythmias requiring continuous antiarrhythmic therapy (subjects with stable atrial fibrillation controlled solely by β-blockers may be included after investigator assessment);
• Unstable angina;
• Myocardial infarction within 12 months;
• Cardio contraction time (QTc) >450ms (male) or >470ms (female) (if abnormal, measure three times at ≥2-minute intervals and average; corrected by Fridericia or Bazett method);
• Congenital long QT syndrome or family history.
• Active or uncontrolled severe infection (≥CTCAE grade 2).
• Renal failure requiring hemodialysis or peritoneal dialysis.
• Immunodeficiency including HIV positivity or other acquired/congenital immunodeficiency diseases.
• Uncontrolled autoimmune diseases requiring immunosuppressants or systemic corticosteroids (>10mg prednisone/day equivalent) within 7 days prior to first dose.
• Epilepsy requiring treatment.
• Poorly controlled diabetes (fasting blood glucose >10mmol/L).
• Tumor-related conditions and treatments:

• Chemotherapy, immunotherapy, or small-molecule targeted therapy within 3 weeks prior to first dose or within 5 half-lives (whichever shorter); prior local radiotherapy allowed if: completed >4 weeks (>2 weeks for brain) before study treatment, and target lesions are outside radiation field or show progression within field;
• National Medical Products Administration (NMPA)-approved traditional Chinese medicines with antitumor indications within 1 week prior to first dose;
• Tumor invading major vessels or judged likely to cause fatal hemorrhage;
• Uncontrolled effusions/ascites requiring recurrent drainage;
• Spinal cord compression, leptomeningeal metastases, or brain metastases with symptoms controlled <4 weeks, or requiring steroids/dehydrating agents within 2 weeks before treatment.
• Known hypersensitivity to study drug or excipients.
• Prior treatment with: Epidermal Growth Factor Receptor/cellular-mesenchymal epithelial transition factor (EGFR/c-Met)-targeted antibody-drug conjugates (ADCs); or topoisomerase I inhibitors (Non-Small Cell Lung Cancer only) or topoisomerase I inhibitor-based ADCs.
• Prior EGFR/c-Met-targeted Monoclonal Antibody (mAbs)/bispecifics with: ≥grade 4 toxicity, permanent discontinuation due to toxicity, ≥grade 3 infusion reactions, or ≥grade 3 myalgia.
• Participation in other antitumor clinical trials within 4 weeks prior to first dose.
• Other conditions judged by investigator to jeopardize subject safety or study completion.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 38 centers

• Cancer Hospital Chinese Academy of Medical Sciences — Beijing
• Beijing Chest Hospital，Capital Medical University — Beijing
• Chongqing University Affiliated Three Gorges Hospital — Chongqing
• The first affiliated hospital of Guangzhou medical university — Guangzhou
• The first affiliated hospital of Guangzhou medical university — Guanzhou
• Zhongshan City People's Hospital — Zhongshan
• Guangxi Medical University Cancer Hospital — Nanning
• Guangxi Medical University Cancer Hospital — Nanning
• … and 30 more centers

Identifiers

NCT: NCT07367529 · TQB6411-Ib/II-02

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗